// App-Quantinova.ai

P422 : Sustained corticosteroid-free remission with vedolizumab in moderate-to-severe ulcerative colitis: A post hoc analysis of GEMINI 1

Researchers

Presenter

  • E V Loftus

Principal Investigators

  • B E Sands

  • J -F Colombel

  • I Dotan

  • J M Khalid

  • D Tudor

  • P Geransar

Medical Centers

  • Icahn School of Medicine at Mount Sinai, Department of Health Evidence and Policy, New York, United States

  • Pathology, The Mount Sinai Hospital, New York, NY

  • Rabin Medical Center, Cardiology, Petah Tikva, Israel

  • Takeda Development Centre Europe Ltd., Evidence and Value Generation, London, UK

  • Takeda Pharmaceutical International AG, Zürich, Switzerland

  • Takeda Pharmaceuticals International AG, GI Rare Medical Affairs, Zurich, Switzerland

Locations

  • United States

  • Israel

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • Tumor necrosis factor

Drug/Treatment

  • Entyvio

  • Prednisone

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • I

Study Id's

  • NCT00783718

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved